Clinical Trial

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

Study acronym: PROTRACT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction \<2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer post abiraterone setting.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2019-07-09; most recent amendment 2025-08-15.
Status change: Recruiting → Active, Not Recruiting 2025-08-15
Status change: Active, Not Recruiting → Recruiting 2020-10-28
Status change: Not Yet Recruiting → Active, Not Recruiting 2020-10-14
Trial Details
NCT Number NCT04015622
Lead Sponsor British Columbia Cancer Agency
Conditions Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enrollment 100 participants
Start Date 2020-10-07
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-20